Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
5 Solid Stocks to Watch That Recently Hiked Dividends
09:01am, Tuesday, 31'st Oct 2023
AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation (MCBC) recently hiked dividends.
Is AbbVie Still a Good Dividend Stock to Buy?
05:23am, Tuesday, 31'st Oct 2023
AbbVie's best-selling product lost patent-protected market exclusivity in the U.S. this year. Competition with lower-cost biosimilar versions of Humira is expected to shrink earnings for at least a co
Why AbbVie Stock Was a Winner on Monday
07:07pm, Monday, 30'th Oct 2023
What a difference a single trading day makes -- the shares slumped notably on Friday. This occurred in the wake of the company's latest quarterly earnings report.
2 No-Brainer Dividend Stocks to Buy This Week
09:15am, Monday, 30'th Oct 2023
Value-laden dividend stocks often deliver superior returns compared to other asset classes. AbbVie, a top dividend growth stock, trades at a rock-bottom multiple, despite its above-average yield.
NEXGEL announces supply agreement with AbbVie
08:51am, Monday, 30'th Oct 2023
NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be a supplier of gel pads to be used with Ab
Why AbbVie Stock Fell Today
03:06pm, Friday, 27'th Oct 2023
AbbVie stock fell today despite easily exceeding estimates for its third quarter. Revenue declines across AbbVie's immunology, oncology, and aesthetics portfolios were partially offset by strong growt
AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript
01:34pm, Friday, 27'th Oct 2023
AbbVie Inc. (NYSE:ABBV ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief
AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View
12:02pm, Friday, 27'th Oct 2023
AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.
AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates
10:35am, Friday, 27'th Oct 2023
AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago.
Abbvie surprises in 3Q with better than expected Humira sales
10:31am, Friday, 27'th Oct 2023
Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and better-than-expected Humira performance. During 3Q 2023 Abbvie (NYSE:AB
High-yield, deep-value AbbVie fell off the patent cliff and lived
09:51am, Friday, 27'th Oct 2023
Shares of AbbVie Inc. NYSE: ABBV have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company's results but has done nothing
AbbVie's Humira Sales Sink 36% but Guidance Lifted on Growth From Other Drugs
08:28am, Friday, 27'th Oct 2023
AbbVie raises earnings guidance for fiscal 2023.
AbbVie raises profit forecast after Humira, newer drugs drive results beat
07:42am, Friday, 27'th Oct 2023
AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand
AbbVie results beat expectations despite low-cost competition to blockbuster Humira
07:42am, Friday, 27'th Oct 2023
AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook, even as its blockbuster autoimmune drug Humira wr
Why Earnings Season Could Be Great for AbbVie (ABBV)
12:02pm, Thursday, 26'th Oct 2023
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
